Neeraj Agarwal: Zr-girentuximab PET–CT for detecting ccRCC

Neeraj Agarwal shared a post on X, about recent paper published in The Lancet Oncology:

Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.

Authors: Brian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, Michael A Morris, Viraj Master, Andrew M Scott, Charles van Praet, Clement Bailly, Bülent Önal, Tamer Aksoy, Robin Merkx, David M Schuster, Sze Ting Lee, Neeta Pandit-Taskar, Alice C Fan, Phillip Allman, Karl Schmidts, Libuse Tauchmanova, Michael Wheatcroft, Christian Behrenbruch, Colin R W Hayward, Peter Mulders.

”Just in The Lancet Oncology.

Zr-girentuximab PET–CT is highly accurate for detecting clear cell renal cell carcinoma (ccRCC), like PSMA-PET in prostate cancer. Congratulations, Brian Shuch et al, on these practice-impacting data. Open access.”

Source: Neeraj Agarwal/X

Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.